logo
Indian economy devastated by five Modi-inflicted shocks: Congress

Indian economy devastated by five Modi-inflicted shocks: Congress

Indian Express4 days ago
The Congress on Friday claimed that the Indian economy has been well and truly devastated by a series of 'five Modi-inflicted shocks', and said the government as well as its cheerleaders are being economical with the truth of the real state of the economy.
Congress general secretary in-charge communications Jairam Ramesh said the Modi government, its drumbeaters and cheerleaders are living in a make-believe world.
The opposition party's assertions came a day after former Congress president and Leader of Opposition in the Lok Sabha Rahul Gandhi said everybody except Prime Minister Narendra Modi and Finance Minister Nirmala Sitharaman know that the country's economy is 'dead'.
In a post on X, Ramesh said, 'Over the past decade, the Indian economy has been well and truly devastated by a series of five Modi-inflicted shocks. Nobody else can be held responsible.' He said demonetisation completely disrupted our growth momentum and destroyed the livelihoods of crores of Indians.
'A fundamentally flawed GST–that is a Tax that is neither Good nor Simple–has wreaked havoc on thousands of business enterprises across the country, except the large companies who can afford to pay the cost associated with GST compliance,' Ramesh said.
He further claimed that the record imports from China have led to the closure of lakhs of MSMEs across the country–in Gujarat alone, around a third of the MSMEs in the stainless steel industry have shut down their operations.
Exports in key areas are dependent on imports of raw materials, components, and intermediates from China, he said.
Ramesh pointed out that private investment has lost the buoyancy it demonstrated during 2004-14.
'Indian industrialists are acquiring citizenship of other countries in an ever increasing measure. The politically motivated and extortionist Raid Raj, coupled with the proliferation of Modani's tentacles, has led to a loss of confidence in the Indian economy,' Ramesh alleged.
He argued that wages for the majority of Indians have stagnated in the last decade, across sectors and across classes.
'This is particularly so in rural India. Household savings have fallen sharply just as household debt has ballooned. Private mass consumption, one of the key drivers of growth, is sputtering just as luxury consumption has not ebbed, clearly pointing to sharpening economic inequalities,' the Congress leader said.
'The Modi government, its drumbeaters and cheerleaders are living in a make-believe world. They are being economical with the truth of the real state of the economy,' Ramesh said.
On Thursday, Gandhi had alleged that the BJP-led government has destroyed the country's economic, defence and foreign policies, and is 'running the country to the ground'.
Speaking with reporters in the Parliament House complex, Gandhi had also claimed that a trade deal with the US will happen and US President Donald Trump will define it.
Asked about Trump calling the Indian economy 'dead', the Congress leader had said, 'He is right, everybody knows this except the prime minister and the finance minister. Everybody knows that the Indian economy is a dead economy. I am glad that President Trump has stated a fact.' He had alleged that the BJP has destroyed the Indian economy.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Economic Times

timea few seconds ago

  • Economic Times

Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO

Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'

Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead

Hans India

time3 minutes ago

  • Hans India

Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead

New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.

UP CM Adityanath, BSP chief Mayawati express grief over Satyapal Malik's death
UP CM Adityanath, BSP chief Mayawati express grief over Satyapal Malik's death

Hans India

time3 minutes ago

  • Hans India

UP CM Adityanath, BSP chief Mayawati express grief over Satyapal Malik's death

Lucknow: Uttar Pradesh Chief Minister Yogi Adityanath and BSP chief Mayawati on Tuesday expressed grief over the death of Satyapal Malik, the former governor of Jammu and Kashmir. In a post on X in Hindi, CM Adityanath said, "The demise of former governor Satyapal Malik ji is extremely sad. Humble tribute! My condolences are with the bereaved family. I pray to God to grant salvation to the departed soul and strength to the bereaved family to bear this sorrow. Om Shanti!" Condoling the death of Malik, BSP chief Mayawati in a post on X in Hindi said, "The news of the death of Shri Satyapal Malik, who was the governor of many states, including Jammu and Kashmir, today is very sad. My deepest condolences to his bereaved family and all his supporters. May nature give them the strength to bear this sorrow." Malik (79) died on Tuesday at a hospital in New Delhi after a prolonged illness, his personal staff said. He was 79. Malik, who had also held the positions of governor of Goa, Bihar, Meghalaya, and Odisha, besides being a member of the Lok Sabha and the Rajya Sabha in his long political career, died at 1.12 pm at the Ram Manohar Lohia hospital in New Delhi. He was in the ICU of the hospital for a long time, getting treatment for various ailments, the staff said. In his gubernatorial role in Jammu and Kashmir, Malik oversaw the abrogation of Article 370 and the bifurcation of the state into two Union Territories on August 5, 2019. Coincidentally, he took his last breath on the sixth anniversary of the Centre's move. Malik attracted a lot of controversy after alleging that he was offered a bribe to clear files of two major projects in Jammu and Kashmir and questioned the BJP-led central government over issues related to farmers and the Pulwama terror attack, among others.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store